Spermatech licenses Dotmatics Platform to support their male contraceptive research

Spermatech licenses Dotmatics Platform to support their male contraceptive research
October 30, 2012

BISHOPS STORTFORD, England--(BUSINESS WIRE)--Dotmatics Limited, a leading supplier of scientific informatics solutions to the Biotech industry, announced today that Spermatech AS, an early drug discovery company based in Oslo, has selected the Dotmatics Platform as their central system to manage and analyse their scientific data.

Spermatech is an early drug development company that is focused on identifying small molecules which can be developed into a non-hormonal male contraceptive. Spermatech's complex research involves working with the sperm specific proteins involved in fertilisation as drug targets. Highly specialised assay tests have been developed to identify drug-like candidates with their aim being to develop an oral birth control pill for men. A diverse and large set of data ranging from chemistry leads to biological assays and protein sequencing will now be managed and analysed through the Dotmatics Platform. Experimental information will be handled using Studies Notebook, a comprehensive and unified electronic laboratory notebook (ELN) for Chemistry and Biology. Spermatech will also use Browser as their single query and reporting system and Vortex as their data analysis and visualisation tool. These modules combined with the rest of the Dotmatics Platform will provide complete informatics management of the Spermatech's data workflow.

"Managing and analysing data is a key component of our research strategy. After a detailed evaluation of the informatics software available in the market, we have chosen Dotmatics because it provides us with all the functionalities that we need, and more, in a single platform" said Tuva Holt-Hereng, Spermatech's CSO. "We are very excited and eager to start working with the Dotamtics Platform as we believe it will streamline our research, making it more effective, leading to results faster" she added.

"We welcome Spermatech to our ever-growing customer base. It is great to see our tools being applied within diverse biotechnology companies," said Dr. Stephen Gallagher, CEO of Dotmatics. "This deployment is a demonstration that Dotmatics solutions have the depth and breadth to completely support complex research operations" he concluded.

About Dotmatics

Dotmatics has rapidly emerged as a preferred informatics supplier to many of the world's largest global Pharmaceutical, Biotechnology and Academic organisations. Dotmatics is a scientific software company deploying web-based knowledge solutions that dramatically improve the way scientific data is queried, managed and shared within companies. Dotmatics has significant expertise in Cheminformatics and Bioinformatics techniques including Chemical databases, SAR analysis, data management and data visualisation. A privately owned company, Dotmatics was founded in 2005 and has its head office based south of Cambridge, UK.


Dotmatics Limited
Dr. Mariana Vaschetto
Tel (Europe): +44(0)1279 654 123
Tel (US West Coast): +1 (619) 419 2808
Tel (US East Coast): +1 (781) 281 2330
Fax: +44(0)1279 653 088
Email: [email protected]

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.